Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856108 | 0.95 | ALDH1A1 (0.46) | NPC1RAB9ASMN1; SMN2LMNAGPR88 | |
| SCHEMBL4854665 | 0.90 | ALDH1A1 (0.48) | SMN1; SMN2LMNAGPR88ALDH1A1MAPT | |
| SCHEMBL4856083 | 0.85 | EPHX2 (0.47) | NPC1RAB9ASMN1; SMN2LMNATLR2 | |
| SCHEMBL4851330 | 0.84 | PPID (0.52) | SMN1; SMN2LMNAALDH1A1TSHRMAPT | |
| SCHEMBL4853624 | 0.83 | TLR2 (0.45) | NPC1RAB9ASMN1; SMN2LMNATLR2 | |
| SCHEMBL4854086 | 0.82 | ALDH1A1 (0.48) | SMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL4855380 | 0.81 | TSHR (0.43) | NPC1RAB9ASMN1; SMN2LMNATLR2 | |
| SCHEMBL28280509 | 0.81 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2LMNAGPR88 | |
| SCHEMBL8996527 | 0.80 | MEN1 (0.51) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4852674 | 0.80 | MEN1 (0.51) | SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1493819-B1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | UBE INDUSTRIES (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-7449325-B2 | Process for enzymatically producing either optically active N-substituted β-amino acids or esters thereof or optically active N-substituted 2-homopipecolic acids or esters thereof | UBE INDUSTRIES, LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | UBE INDUSTRIES, LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1493819-A1 | PROCESS FOR PRODUCING EITHER OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID AND OPTICALLY ACTIVE N-SUBSTITUTED BETA-AMINO ACID ESTER OR OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID AND OPTICALLY ACTIVE N-SUBSTITUTED 2-HOMOPIPECOLIC ACID ESTER | Ube Industries, Ltd. (JP) | 2005-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050170473-A1 | Process for producing either optically active n-substituted beta-amino acid and optically active n-substituted beta-amino acid ester or optically active n-substituted 2-homopipecolic acid and optically active n-substituted 2-homopipecolic acid ester | CYP8B1, SRR, HM13 | NPC1 1932/4885RAB9A 1336/4885SMN1; SMN2 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.